Pseudoginsenoside RT5
Based on 1 Customer Validation
Pseudoginsenoside RT5 is an orally active ocotillol-type ginsenoside and Antibacterial agent. Pseudoginsenoside RT5 can be isolated from American ginseng, transgenic American ginseng crown gall tumors and Panax japonicus. Pseudoginsenoside RT5 exerts cardioprotective effects against myocardial injury, and also possesses antibacterial and antitumor activities. Pseudoginsenoside RT5 can be used in research related to Alzheimer's disease, myocardial injury, tumors and bacterial infections.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.55%
- CAS No.: 98474-78-3
- Formule: C36H62O10
- Masse moléculaire:654.87
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Pseudoginsenoside RT5 exhibits significant biological activities, including cardioprotective effects against myocardial injury, as well as antibacterial and antitumor properties[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | AUC0-∞ | MRT0-t | MRT0-∞ | Vd | CL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[2] | 40 mg/kg | p.o. | 8.88 h | 0.67 h | 105.75 ng/mL | 757.02 ng·h/mL | 1,000.63 ng·h/mL | 6.86 h | 12.68 h | 495.33 L/kg | 54.05 L/h/kg |
| Dog[2] | 15 mg/kg | p.o. | 2.89 h | 1.75 h | 3,020.93 ng/mL | 16,817.47 ng·h/mL | 17,008.57 ng·h/mL | 5.24 h | 5.45 h | 3.65 L/kg | 0.90 L/h/kg |
Pseudoginsenoside RT5 (15 mg/kg; p.o.; single dose) administered orally to healthy beagle dogs results in systemic exposure with a Cmax of 3,020.93 ng/mL, an AUC0-t of 16,817.47 ng/h/mL, and a terminal half-life of 2.89 h[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (both genders, 200-220 g)[2]
-
Dosage:40 mg/kg
-
Administration:p.o.; single dose
-
Result:Reached a peak plasma concentration (Cmax) of 105.75 ng/mL at a time to peak (Tmax) of 0.67 h.
Achieved an area under the plasma concentration versus time curve from 0 to the last measured time point (AUC(0-t)) of 757.02 ng/h/mL, and an AUC from 0 to infinity (AUC(0-∞)) of 1,000.63 ng/h/mL.
Had a terminal half-life (T1/2) of 8.88 h, a mean residence time from 0 to the last measured time point (MRT(0-t)) of 6.86 h, and an MRT from 0 to infinity (MRT(0-∞)) of 12.68 h.
Exhibited a volume of distribution (Vd) of 495.33 L/kg, and systemic clearance (CL) of 54.05 L/h/kg.
Showed a double peak in the plasma concentration versus time profile.
-
Animal Model:Beagle (both genders, 8-12 kg)[2]
-
Dosage:15 mg/kg
-
Administration:p.o.; single dose
-
Result:Reached a peak plasma concentration (Cmax) of 3,020.93 ng/mL at a time to peak (Tmax) of 1.75 h.
Achieved an area under the plasma concentration versus time curve from 0 to the last measured time point (AUC(0-t)) of 16,817.47 ng/h/mL, and an AUC from 0 to infinity (AUC(0-∞)) of 17,008.57 ng/h/mL.
Had a terminal half-life (T1/2) of 2.89 h, a mean residence time from 0 to the last measured time point (MRT(0-t)) of 5.24 h, and an MRT from 0 to infinity (MRT(0-∞)) of 5.45 h.
Exhibited a volume of distribution (Vd) of 3.65 L/kg, and systemic clearance (CL) of 0.90 L/h/kg.
Showed a double peak in the plasma concentration versus time profile.
Chemical Information
-
CAS No. 98474-78-3
-
Appearance Solid
-
Masse moléculaire 654.87
-
Formule C36H62O10
-
Color White to off-white
-
SMILES
C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]4O)O)([H])O[C@@H]4CO)[C@@]2([H])C3(C)C)[C@]5([C@@]1([H])[C@]([C@]6(O[C@@H](C(C)(O)C)CC6)C)([H])CC5)C
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvant et solubilité
DMSO : 100 mg/mL (152.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.82 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhu JH, et al. Two new compounds from transgenic Panax quinquefolium. Fitoterapia. 2010;81(5):339-342. [Content Brief]
[2]. Li Y, et al. Pharmacokinetic Characterizations of Ginsenoside Ocotillol, RT5 and F11, the Promising Agents for Alzheimer's Disease from American Ginseng, in Rats and Beagle Dogs. Pharmacology. 2019;104(1-2):7-20. [Content Brief]
[3]. Li P, et al. Characterization and protein engineering of a novel UDP-glycosyltransferase involved in pseudoginsenoside Rt5 biosynthesis from Panax japonicus. Int J Biol Macromol. 2024;277(Pt 4):134537. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5270 mL | 7.6351 mL | 15.2702 mL | 38.1755 mL |
| 5 mM | 0.3054 mL | 1.5270 mL | 3.0540 mL | 7.6351 mL | |
| 10 mM | 0.1527 mL | 0.7635 mL | 1.5270 mL | 3.8176 mL | |
| 15 mM | 0.1018 mL | 0.5090 mL | 1.0180 mL | 2.5450 mL | |
| 20 mM | 0.0764 mL | 0.3818 mL | 0.7635 mL | 1.9088 mL | |
| 25 mM | 0.0611 mL | 0.3054 mL | 0.6108 mL | 1.5270 mL | |
| 30 mM | 0.0509 mL | 0.2545 mL | 0.5090 mL | 1.2725 mL | |
| 40 mM | 0.0382 mL | 0.1909 mL | 0.3818 mL | 0.9544 mL | |
| 50 mM | 0.0305 mL | 0.1527 mL | 0.3054 mL | 0.7635 mL | |
| 60 mM | 0.0255 mL | 0.1273 mL | 0.2545 mL | 0.6363 mL | |
| 80 mM | 0.0191 mL | 0.0954 mL | 0.1909 mL | 0.4772 mL | |
| 100 mM | 0.0153 mL | 0.0764 mL | 0.1527 mL | 0.3818 mL |
Pseudoginsenoside RT5 Related Classifications
HY-N0542 Related Classifications
Powered by Bioz